期刊文献+

高通量测序分析肠易激综合征患者和健康人肠道菌群差异 被引量:3

High-throughput Sequencing Analysis of Intestinal Microbiota in Patients with Irritable Bowel Syndrome and Healthy Individuals
下载PDF
导出
摘要 目的通过高通量测序方法分析肠易激综合征患者(Irritable Bowel Syndrome,IBS)和健康人肠道菌群差异。方法采用Illumima系统Mi Seq平台对正常组和IBS组粪便进行16S r RNA测序。结果 IBS患者的肠道菌群多样性无显著变化。在门水平上,Firmicutes丰度显著增加(P<0.01),Bacteroidete的丰度和Bacteroidetes/Firmicutes的比值下降。在科水平上,正常组和IBS组粪便肠道菌群中检测到Cryomorphaceae、Erysipelotrichaceae、Campylobacteraceae和Fibrobacteraceae,且丰度变化具有显著差异(P<0.05)。结论 IBS患者和健康人相比,肠道菌群多样性未见明显差异。但某些细菌菌种存在显著差异。 To compare differences of intestinal microbiotabetween IBS patients andhealthy by using high-throughput sequencing technology. Methods The feces were collected IBS group andhealthy group. The community structure and abundance of intestinal microbiota were examined via analyzing 16S rRNA high throughput sequencing using Illumima System. Results The diversifies of intestinal bacteria were no significant differences in IBS group. In phyla level, the abundance of Firmicutes was significantlyincreased (P〈0.01), while the abundance of Bacteroidetesand the ratio of Bacteroidetes/Firmicutes were decreased (P〈0.01). Besides, in family level, cryomorphaceae,erysipelotrichac eae. Campylobacteraceae and fibrobacteraceae were detected in IBS group and healthy group.Their abundance were significantly difference, respectively (P〈0.05). Conclusion No significantdifferences in the bacterial diversity indices are found, but some bacterial species significantly differbetween the patients with IBS and healthy controls.
作者 杨莉丽 王成文 邹傲 YANG Li-li WANG Cheng-wen ZOU Ao(Shantou University Medical College, Shantou 515041, Guangdong Province, China)
出处 《罕少疾病杂志》 2017年第5期37-39,共3页 Journal of Rare and Uncommon Diseases
基金 深圳市科技计划项目:No.JCYJ201404151625429
关键词 肠易激综合征 肠道菌群 高通量测序 16S RRNA Irritable Bowel Syndrome Intestinal Microbiota High-throughput Sequencing 16S rRNA
  • 相关文献

参考文献3

二级参考文献65

  • 1Thomas Julius Borody,Jordana Campbell.Fecal Microbiota Transplantation[J].Gastroenterology Clinics of North America.2012(4)
  • 2Wolfgang Kruis,Sigrun Chrubasik,Stephan Boehm,Christiane Stange,Juergen Schulze.A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome[J].International Journal of Colorectal Disease.2012(4)
  • 3Bong Ki Cha,Seung Mun Jung,Chang Hwan Choi,In-Do Song,Hyun Woong Lee,Hyung Joon Kim,Jae Hyuk,Sae Kyung Chang,Kijeong Kim,Won-Seok Chung,Jae-Gu Seo.The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial[J].Journal of Clinical Gastroenterology.2012(3)
  • 4J. F.Cryan,E. M.Quigley.Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria[J].Aliment Pharmacol Ther.2012(4)
  • 5Martin J. Grehan,Thomas Julius Borody,Sharyn M. Leis,Jordana Campbell,Hazel Mitchell,Antony Wettstein.Durable Alteration of the Colonic Microbiota by the Administration of Donor Fecal Flora[J].Journal of Clinical Gastroenterology.2010(8)
  • 6Alexander Khoruts,Johan Dicksved,Janet K. Jansson,Michael J. Sadowsky.Changes in the Composition of the Human Fecal Microbiome After Bacteriotherapy for Recurrent Clostridium difficile-associated Diarrhea[J].Journal of Clinical Gastroenterology.2010(5)
  • 7J. M.JARCHO,L.CHANG,S. M.BERMAN,B.SUYENOBU,B. D.NALIBOFF,M. D.LIEBERMAN,V. Z.AMEEN,M. A.MANDELKERN,E. A.MAYER.Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5‐HT&lt;sub&gt;3&lt;/sub&gt; receptor antagonist: a pilot study[J].Alimentary Pharmacology & Therapeutics.2008(3)
  • 8M. A.MCNALLY,G. R.LOCKE,A. R.ZINSMEISTER,C. D.SCHLECK,J.PETERSON,N. J.TALLEY.Biliary events and an increased risk of new onset irritable bowel syndrome: a population‐based cohort study[J].Alimentary Pharmacology & Therapeutics.2008(3)
  • 9A.Agrawal,P. J.Whorwell.Abdominal bloating and distension in functional gastrointestinal disorders – epidemiology and possible mechanisms: authors’ reply[J].Alimentary Pharmacology & Therapeutics.2008(8)
  • 10A.AGRAWAL,P. J.WHORWELL.Review article: abdominal bloating and distension in functional gastrointestinal disorders – epidemiology and exploration of possible mechanisms[J].Alimentary Pharmacology & Therapeutics.2007(1)

共引文献33

同被引文献13

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部